Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leo Rasche

Showing results (51-60 of 170) with videos related to

Pageof 17
Sort By:
Blood Cancer Journal|March 22, 2022
Extramedullary disease in multiple myeloma: a systematic literature reviewJoan Bladé, Meral Beksac, Jo Caers, et al.
Annals of Hematology|February 12, 2021
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patternsSophia Danhof, Leo Rasche, Anja Mottok, et al.
Clinical Nuclear Medicine|May 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Clinical Nuclear Medicine|March 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Journal of Cancer Research and Clinical Oncology|July 19, 2023
A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trialsAnna Fleischer, Larissa Zapf, Johannes Allgaier, et al.
Journal of Hematology & Oncology|June 7, 2022
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?David Kegyes, Catalin Constantinescu, Louise Vrancken, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapiesMarios Papadimitriou, Sungwoo Ahn, Benjamin Diamond, et al.
Journal of Clinical Medicine|July 21, 2019
Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma ResearchSophia Loda, Jonathan Krebs, Sophia Danhof, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2019
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11Johannes Duell, Dragana S Lukic, Margarete Karg, et al.
Cancers|April 29, 2020
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary DiseaseXiang Zhou, Patricia Flüchter, Katharina Nickel, et al.
Pageof 17

Showing results (51-60 of 170) with videos related to

Sort By:
Pageof 17
Blood Cancer Journal|March 22, 2022
Extramedullary disease in multiple myeloma: a systematic literature reviewJoan Bladé, Meral Beksac, Jo Caers, et al.
Annals of Hematology|February 12, 2021
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patternsSophia Danhof, Leo Rasche, Anja Mottok, et al.
Clinical Nuclear Medicine|May 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Clinical Nuclear Medicine|March 5, 2025
Myeloablative Radioligand Therapy Targeting C-X-C Motif Chemokine Receptor 4 in Advanced Multiple MyelomaNiklas Dreher, Anna-Lena Dörrler, Sabrina Kraus, et al.
Journal of Cancer Research and Clinical Oncology|July 19, 2023
A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trialsAnna Fleischer, Larissa Zapf, Johannes Allgaier, et al.
Journal of Hematology & Oncology|June 7, 2022
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?David Kegyes, Catalin Constantinescu, Louise Vrancken, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapiesMarios Papadimitriou, Sungwoo Ahn, Benjamin Diamond, et al.
Journal of Clinical Medicine|July 21, 2019
Exploration of Artificial Intelligence Use with ARIES in Multiple Myeloma ResearchSophia Loda, Jonathan Krebs, Sophia Danhof, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 16, 2019
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11Johannes Duell, Dragana S Lukic, Margarete Karg, et al.
Cancers|April 29, 2020
Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary DiseaseXiang Zhou, Patricia Flüchter, Katharina Nickel, et al.
Pageof 17